Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in endometrial cancer, while reporting higher first-quarter revenue and reaffirming full-year guidance.
On the company’s first-quarter earnings call, President and CEO Richard Paulson said Karyopharm has focused its organization on advancing late-stage clinical programs, maintaining its commercial base in multiple myeloma and managing expenses as it approaches “significant value-creating milestones.”
